Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.(1,2) Severely affected patients are often treated with immune-modulating systemic drugs.(3,4) On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.
author ๐Ÿ‘ค Wollenberg, Andreas ๐Ÿ‘ค Flohr, Carsten ๐Ÿ‘ค Simon, Dagmar ๐Ÿ‘ค Cork, Michael J ๐Ÿ‘ค Thyssen, Jacob P ๐Ÿ‘ค Bieber, Thomas ๐Ÿ‘ค de Bruin-Weller, Marjolein S ๐Ÿ‘ค Weidinger, Stephan ๐Ÿ‘ค Deleuran, Mette ๐Ÿ‘ค Taieb, Alain ๐Ÿ‘ค Paul, Carle ๐Ÿ‘ค Trzeciak, Magdalena ๐Ÿ‘ค Werfel, Thomas ๐Ÿ‘ค Seneschal, Julien ๐Ÿ‘ค Barbarot, Sebastien ๐Ÿ‘ค Darsow, Ulf ๐Ÿ‘ค Torrelo, Antonio ๐Ÿ‘ค Stalder, Jean-Francois ๐Ÿ‘ค Svensson, Ake ๐Ÿ‘ค Hijnen, Dirkjan ๐Ÿ‘ค Gelmetti, Carlo ๐Ÿ‘ค Szalai, Zsuzsanna ๐Ÿ‘ค Gieler, Uwe ๐Ÿ‘ค De Raeve, Linda ๐Ÿ‘ค Kunz, Barbara ๐Ÿ‘ค Spuls, Phyllis ๐Ÿ‘ค von Kobyletzki, Laura B ๐Ÿ‘ค Folster-Holst, Regina ๐Ÿ‘ค Chernyshov, Pavel V ๐Ÿ‘ค Cristen-Zaech, Stephanie ๐Ÿ‘ค Heratizadeh, Annice ๐Ÿ‘ค Ring, Johannes ๐Ÿ‘ค Vestergaard, Christian
year โฐ 2020
issn ๐Ÿ—„
volume
number
page
citedbycount 0